Perjeta Injection, Solution, Concentrate
Product Images NDC 50242-145

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Perjeta (NDC 50242-145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Perjeta 01)

A Kaplan-Meier survival curve illustrating the proportion of patients event-free over time in months. It compares two randomized treatments: Pertuzumab plus Trastuzumab and Docetaxel (dashed line) versus Placebo plus Trastuzumab and Docetaxel (solid line). The graph shows hazard ratio (HR = 0.62), 95% confidence interval (0.51 to 0.75), and a p-value less than 0.0001. The number of patients at risk at different time points is indicated below the x-axis.*

FDA Label Image

Figure 2 (Perjeta 02)

A Kaplan-Meier survival curve graph showing the proportion of subjects event-free over time (months) comparing two randomized treatment groups: Ptzo + T + D (dashed line) and Pla + T + D (solid line). The graph includes hazard ratio (HR=0.68), confidence interval (95% CI 0.56-0.84), and p-value (0.0002), with numbers at risk over several time points provided below the x-axis.*

FDA Label Image

Figure 3 (Perjeta 03)

A Kaplan-Meier survival curve chart showing the proportion of event-free patients over 60 months comparing two treatment groups: Ptz+H+Chemo (black line) and Pla+H+Chemo (gray line). The chart includes the number of patients at risk at various time points and statistical data such as p-value (0.0471) and Stratified Hazard Ratio with 95% CI (0.82, 0.67 to 1.00).*

FDA Label Image

Principal Display Panel (14 mL Vial Carton)

Label for PERJETA (Pertuzumab) injection concentrate, 30 mg/mL, with a total of 420 mg in 14 mL. The label indicates intravenous infusion use, single-dose vial, to be diluted prior to use, and discard any unused portion. The product is supplied by Genentech, Inc. and displays the NDC 50242-145-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.